Bridge Medicines

Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.

 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.